Probiotics in pediatric liver disease

Journal of Clinical Gastroenterology

Volumn 49, Issue , 2015, Pages S33-S36

  Miloh, Tamir ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Children; Lactobacillus; Liver; Probiotics; VSL 3

Indexed keywords

ALANINE AMINOTRANSFERASE; CALGRANULIN; HEPATITIS B VACCINE; PROBIOTIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIFIDOBACTERIUM LONGUM; BODY MASS; CHILDHOOD DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; ENTERITIS; FAMILIAL HYPERCHOLESTEROLEMIA; HEPATITIS B; HUMAN; LIFESTYLE MODIFICATION; LIVER DISEASE; LIVER FIBROSIS; LIVER GRAFT; META ANALYSIS (TOPIC); NECROTIZING ENTEROCOLITIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SYSTEMATIC REVIEW; ADVERSE EFFECTS; CHILD; INFANT; INTESTINE FLORA; LIVER; LIVER DISEASES; LIVER TRANSPLANTATION; MICROBIOLOGY; NEWBORN; PARENTERAL NUTRITION; PREMATURITY; PRESCHOOL CHILD; PROCEDURES;

CHILD; CHILD, PRESCHOOL; GASTROINTESTINAL MICROBIOME; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; LIVER; LIVER DISEASES; LIVER TRANSPLANTATION; PARENTERAL NUTRITION; PROBIOTICS;

EID: 84944195029     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000365     Document Type: Article

References (24)

1. Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740-743.
2. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601-609.
3. Aller R, De Luis DA, Izaola O, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090-1095.
4. Malaguarnera M, Vacante M, Antic T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57:545-553.
5. Wong VW, Won GL, Chim AM, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-ofconcept study. Ann Hepatol. 2013;12:256-262.
6. Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: the beneficial effects of VSL# 3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276-1285.
7. Del Campo R, Garriga M, Perez-Aragon A, et al. Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study. J Cyst Fibros. 2014;13:716-722.
8. Fallahi G, Motamed F, Yousefi A, et al. The effect of probiotics on fecal calprotectin in patients with cystic fibrosis. Turk J Pediatr. 2013;55:475-478.
9. Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther. 2004;20:813-819.
10. Di Nardo G, Oliva S, Menichella A, et al. Lactobacillus reuteri ATCC55730 in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2014;58:81-86.
11. Jafari SA, Mehdizadeh-Hakkak A, Kianifar HR, et al. Effects of probiotics on quality of life in children with cystic fibrosis; a randomized controlled trial. Iran J Pediatr. 2013;23:669-674.
12. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid Based Child Health. 2014;9:584-671.
13. Soh SE, Ong DQ, Gerez I, et al. Effect of probiotic supplementation in the first 6 months of life on specific antibody responses to infant Hepatitis B vaccination. Vaccine. 2010;28:2577-2579.
14. Guardamagna O, Amaretti A, Puddu PE, et al. Bifidobacteria supplementation: effects on plasma lipid profiles in dyslipidemic children. Nutrition. 2014;30:831-836.
15. Leone L, Malamisura M, De Matteo A, et al. High Blood Pressure and Cardiovascular Prevention. 12th National Congress of the Italian Society of Cardiovascular Prevention, SIPREC 2014 Naples, Italy. 2014;212(151).
16. Pawlowska J, Klewicka E, Czubkowski P, et al. Effect of Lactobacillus casei DN-114001 application on the activity of fecal enzymes in children after liver transplantation. Transplant Proc. 2007;39:3219-3221.
17. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. Pediatrics. 2010;126:1217-1231.
18. Eslamparast T, Poustchi H, Zamani F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99:535-542.
19. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL# 3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39:540-543.
20. Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther. 2014;39:1113-1125.
21. Eguchi S, Takatsuki M, Hidaka M, et al. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study. Am J Surg. 2011;201:498-502.
22. Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin ChestMed. 2007;28:279-288.
23. Jones ML, Martoni CJ, Ganopolsky JG, et al. The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention. Expert Opin Biol Ther. 2014;14:467-482.
24. Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol. 2008;20:688-692.